

532-79

Access DB# \_\_\_\_\_

## SEARCH REQUEST FORM

## Scientific and Technical Information Center

Requester's Full Name: Michele Flood Examiner #: 77454 Date: 10-19-2001  
 Art Unit: 1651 Phone Number 308-9432 Serial Number: 09/646 740  
 Mail Box and Bldg/Room Location: 11801 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Utilization of extracts from Iris Plants, Cimicifuga

Title of Invention: Ranuncosa and Tectorigenin as an estrogen-like  
organ-selective medicament without uterotrophic effects

Inventors (please provide full names): Wolfgang Wuttke; Hubertus Sarry; Ulrich

Christoffel; Barbara Spangler; Michael Popp

Earliest Priority Filing Date: 3/19/1998

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Method for producing an estrogen-type effect without uterotrophic effect comprising administering an Iridaceae extract, with the proviso that Belamcanda chinensis extract is not used to for treating peri-menopausal and post-menopausal disorders, extract comprises tectorigenin and tectorigenic glycoside used to treat/prevent cardiovascular disease, atherosclerosis, osteoporosis, climacteric disorders, prevention/relief of hot flashes.

The claimed method wherein the extract is Belamcanda chinensis.

11-1-01

Claims Attached.

STAFF USE ONLY		Type of Search	Vendors and cost where applicable
Searcher:	Point of Contact: Alex Wacławiw	NA Sequence (#)	STN <input checked="" type="checkbox"/>
Searcher:	Technical Info. Specialist CM1-12C14 Tel: 308-4491	AA Sequence (#)	Dialog
Searcher Location:		Structure (#)	Questel/Orbit
Date Searcher Picked Up:	10-29-01	Bibliographic	Dr. Link
Date Completed:	11-1-01	Litigation	Lexis/Nexis
Searcher Prep & Review Time:	12	Fulltext	Sequence Systems
Clerical Prep Time:		Patent Family	WWW/Internet
Online Time:		Other	Other (specify)

Flood 09/646,740

=> d his

(FILE 'REGISTRY' ENTERED AT 14:37:58 ON 29 OCT 2001)  
DEL HIS Y

FILE 'HCAPLUS' ENTERED AT 14:39:03 ON 29 OCT 2001

FILE 'STNGUIDE' ENTERED AT 14:39:27 ON 29 OCT 2001

'FILE 'REGISTRY' ENTERED AT 14:43:14 ON 29 OCT 2001  
E TECTORIGENIN/CN

L1 1 S E3  
L2 1 S E4

FILE 'HCAPLUS' ENTERED AT 14:44:01 ON 29 OCT 2001

L3 61 S L1 OR L2  
L4 1 S TETORIGENIN?  
L5 76 S TECTORIGENIN?  
L6 86 S L3 OR L5  
L7 394 S IRIDACEAE OR IRIS (L) PLANT#  
L8 0 S BELAMCANDRA CHINESIS  
L9 2 S BELAMCANDA CHINESIS  
L10 55 S BELAMCANDA CHINENSIS  
L11 0 S BELAMCANDRA CHINENSIS  
L12 443 S L10 OR L7 OR L9  
L13 40 S L12 (L) EXT?  
L14 3301 S ANTIARTERIOSCLERO? OR ANTIARTHROSCLER?  
L15 5733 S CARDIOVASCULAR AGENT#  
L16 1 S MENPAUSE  
L17 6989 S OSTEOPOROSIS OR CLIMACTER?  
L18 4846 S MENOPAUSE  
L19 1 S L13 AND (L14-L18)  
L20 1 S L6 AND (L14-L18)  
L21 2 S L7 AND (L14-L18)  
L22 101 S HOT FLASH? AND (L6 OR L14-L18)  
L23 1 S HOT FLASH# AND (L6 OR L12)  
L24 2 S L19 OR L20 OR L21 OR L23  
L25 49162 S ESTROGEN?  
L26 3 S L25 AND (L6 OR L12)  
L27 4 S L24 OR L26

Flood 09/646,740

=> fil reg  
FILE 'REGISTRY' ENTERED AT 14:53:27 ON 29 OCT 2001  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 28 OCT 2001 HIGHEST RN 365210-66-8  
DICTIONARY FILE UPDATES: 28 OCT 2001 HIGHEST RN 365210-66-8

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER see  
HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES  
for more information. See STNote 27, Searching Properties in the CAS  
Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d que 11;d 11  
L1 1 SEA FILE=REGISTRY ABB=ON TECTORIGENIN/CN

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS  
RN 548-77-6 REGISTRY  
CN 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-hydroxyphenyl)-6-methoxy- (9CI)  
(CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Isoflavone, 4',5,7-trihydroxy-6-methoxy- (7CI, 8CI)  
CN Tectorigenin (6CI)  
OTHER NAMES:  
CN K 251T  
FS 3D CONCORD  
MF C16 H12 O6  
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS,  
BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CHEMCATS, DDFU, DRUGU, EMBASE,  
IPA, MEDLINE, MRCK\*, NAPRALERT, RTECS\*, TOXLIT  
(\*File contains numerically searchable property data)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


59 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
59 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

Flood 09/646,740

=> d que 12; d 12  
L2 1 SEA FILE=REGISTRY ABB=ON "TECTORIGENIN 4'-GLUCOSIDE"/CN

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS  
RN 141894-63-5 REGISTRY  
CN 4H-1-Benzopyran-4-one, 3-[4-(.beta.-D-glucopyranosyloxy)phenyl]-5,7-dihydroxy-6-methoxy- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN Tectorigenin 4'-glucoside  
FS STEREOSEARCH  
MF C22 H22 O11  
SR CA  
LC STN Files: AGRICOLA, BEILSTEIN\*, CA, CAPLUS  
(\*File contains numerically searchable property data)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1967 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> fil hcaplus  
FILE 'HCAPLUS' ENTERED AT 14:53:48 ON 29 OCT 2001  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 29 Oct 2001 VOL 135 ISS 19  
FILE LAST UPDATED: 28 Oct 2001 (20011028/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

HCAplus now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic

Flood 09/646,740

information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> d his 13-

(FILE 'REGISTRY' ENTERED AT 14:43:14 ON 29 OCT 2001)

FILE 'HCAPLUS' ENTERED AT 14:44:01 ON 29 OCT 2001

L3 61 S L1 OR L2  
L4 1 S TETORIGENIN?  
L5 76 S TECTORIGENIN?  
L6 86 S L3 OR L5  
L7 394 S IRIDACEAE OR IRIS (L) PLANT#  
L8 0 S BELAMCANDRA CHINESIS  
L9 2 S BELAMCANDRA CHINESIS  
L10 55 S BELAMCANDA CHINENSIS  
L11 0 S BELAMCANDRA CHINENSIS  
L12 443 S L10 OR L7 OR L9  
L13 40 S L12 (L) EXT?  
L14 3301 S ANTIARTERIOSCLERO? OR ANTIARTHROSCLER?  
L15 5733 S CARDIOVASCULAR AGENT#  
L16 1 S MENPAUSE  
L17 6989 S OSTEOPOROSIS OR CLIMACTER?  
L18 4846 S MENOPAUSE  
L19 1 S L13 AND (L14-L18)  
L20 1 S L6 AND (L14-L18)  
L21 2 S L7 AND (L14-L18)  
L22 101 S HOT FLASH? AND (L6 OR L14-L18)  
L23 1 S HOT FLASH# AND (L6 OR L12)  
L24 2 S L19 OR L20 OR L21 OR L23  
L25 49162 S ESTROGEN?  
L26 3 S L25 AND (L6 OR L12)  
L27 4 S L24 OR L26

FILE 'REGISTRY' ENTERED AT 14:53:27 ON 29 OCT 2001

FILE 'HCAPLUS' ENTERED AT 14:53:48 ON 29 OCT 2001

=> d .ca 127 1-4

L27 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2001 ACS  
ACCESSION NUMBER: 2000:761931 HCAPLUS  
DOCUMENT NUMBER: 133:325492  
TITLE: Breast-enlarging agent containing Pueraria root products  
INVENTOR(S): Hirose, Katsutoshi; Katayama, Masato; Hirata, Naonori  
PATENT ASSIGNEE(S): Kobe Tennenbutsu Kagaku K. K., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
JP 2000302667	A2	20001031	JP 1999-115773	19990423

AB The invention relates to a breast-enlarging agent contg. Pueraria root or its product, esp. Pueraria lobata or Pueraria thomsonii, contg. isoflavones. A powder of Puerariae Radix root was combined with vaseline to obtain an ointment. The agent may further use for treatment and

prevention of menopausal syndrome, skin-whitening, or hair growth-stimulation.

IC ICM A61K007-48  
ICS A61K007-00; A61K007-06; A61P017-00; A61P017-14; A61P043-00;  
A61K031-352; A61K035-78

CC 62-4 (Essential Oils and Cosmetics)  
Section cross-reference(s): 63

IT **Menopause**  
(Pueraria root products for menopausal syndrome treatment)

IT **Iridaceae**

Kudzu (Pueraria)  
Kudzu (Pueraria lobata)  
Kudzu (Pueraria thomsoni)  
Mammary gland

(breast-enlarging agent contg. Pueraria root products)

L27 ANSWER 2 OF 4 HCPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:67487 HCPLUS  
DOCUMENT NUMBER: 132:97858  
TITLE: Use of isoflavones to prevent hair loss and preserve  
the integrity of existing hair  
INVENTOR(S): Segelman, Alvin B.  
PATENT ASSIGNEE(S): Natures Sunshine Products, Inc., USA  
SOURCE: U.S., 5 pp.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6017893	A	20000125	US 1997-920955	19970829
PRIORITY APPLN. INFO.:			US 1996-25810	19960830

OTHER SOURCE(S): MARPAT 132:97858

AB The present invention is an orally- or topically-administrable compn. for preventing and treating hair loss. The invention is a plant or plant ext. contg. isoflavones having a weak estrogen activity. The invention further includes methods for using the invented compn. to prevent and treat hair loss. A hair lotion contained concd. semi-purified soybean exts. (contg. 20-50 % isoflavones), progesterone (up to 5 mg/30 mL), and a lotion base.

IC ICM A61K031-70

NCL 514027000

CC 62-3 (Essential Oils and Cosmetics)  
Section cross-reference(s): 63

IT **Estrogens**

RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(as addnl. agent; isoflavones for prevention of hair loss)

IT **Iridaceae**

Legume (Fabaceae)

Marantaceae

Moraceae

Podocarpaceae

Rosaceae

Soybean (Glycine max)

(exts.; isoflavones for prevention of hair loss)

REFERENCE COUNT: 7

REFERENCE(S):  
(1) Anon; JP 05-78347 1993 HCPLUS  
(2) Anon; WO 96/10387 1996 HCPLUS  
(3) Delgado; 1996 HCPLUS  
(4) Hakamata; 1993 HCPLUS  
(5) Kung; US 5639715 1997 HCPLUS

## ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1999:613676 HCAPLUS  
 DOCUMENT NUMBER: 131:223505  
 TITLE: Utilization of extracts from iris plants, Cimicifuga racemosa, and tectorigenin as estrogenlike organ-selective medicaments without uterotrophic effects  
 INVENTOR(S): Wuttke, Wolfgang; Jarry, Hubertus; Christoffel, Volker; Spengler, Barbara; Popp, Michael  
 PATENT ASSIGNEE(S): Plantamed Arzneimittel G.m.b.H., Germany  
 SOURCE: PCT Int. Appl., 27 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9947149	A1	19990923	WO 1999-EP1860	19990319
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9931466	A1	19991011	AU 1999-31466	19990319
BR 9908256	A	20001212	BR 1999-8256	19990319
EP 1064009	A1	20010103	EP 1999-913282	19990319
R: AT, CH, DE, DK, ES, FR, GB, GR, IT, LI, SE, PT				
PRIORITY APPLN. INFO.:			DE 1998-19812204 A	19980319
			WO 1999-EP1860	W 19990319

AB Exts. from iris plants [esp. *Belamcanda sinensis* (Iridaceae)], exts. from *C. racemosa*, and tectorigenin and tectorigenin glycosides obtained from *B. sinensis* are useful as estrogenlike organ-selective medicaments for selective treatment and/or prophylaxis of cardiovascular diseases (esp. arteriolosclerosis), osteoporosis, and climacteric symptoms (e.g. hot flashes). Virtually no uterotrophic effects are obsd. when using these medicaments. Thus, lipophilic components of *C. racemosa* exts. bound strongly to anti-estradiol antibodies and to cytosolic estradiol receptors from pig uterus. Administration of *B. sinensis* ext. i.v. inhibited the pulsatile release of gonadotropin-releasing hormone in ovariectomized rats and inhibited LH secretion, without affecting the expression of uterine genes for VEGF, IGF-1, and C3.

IC ICM A61K035-78  
 ICS A61K031-35

CC 1-8 (Pharmacology)

Section cross-reference(s): 2, 63

ST estrogen iris Cimicifuga Belamcanda; cardiovascular disease estrogen plant ext;  
 osteoporosis estrogen plant ext;  
 climacteric estrogen plant ext;  
 tectorigenin cardiovascular disease osteoporosis  
 climacteric

IT Antiarteriosclerotics  
 (antiatherosclerotics; utilization of exts. from iris plants, Cimicifuga racemosa, and tectorigenin as

estrogenlike organ-selective medicaments without uterotrophic effects)

IT Menopause  
(disorder, hot flash; utilization of exts from iris plants, Cimicifuga racemosa, and tectorigenin as estrogenlike organ-selective medicaments without uterotrophic effects)

IT Menopause  
(disorder; utilization of exts. from iris plants, Cimicifuga racemosa, and tectorigenin as estrogenlike organ-selective medicaments without uterotrophic effects)

IT Osteoporosis  
(therapeutic agents; utilization of exts. from iris plants, Cimicifuga racemosa, and tectorigenin as estrogenlike organ-selective medicaments without uterotrophic effects)

IT Belamcanda chinensis  
Cardiovascular agents  
Cimicifuga racemosa  
Iridaceae  
(utilization of exts. from iris plants, Cimicifuga racemosa, and tectorigenin as estrogenlike organ-selective medicaments without uterotrophic effects)

IT Estrogens  
RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)  
(utilization of exts. from iris plants, Cimicifuga racemosa, and tectorigenin as estrogenlike organ-selective medicaments without uterotrophic effects)

IT 548-77-6, Tectorigenin 548-77-6D,  
Tectorigenin, glycosides  
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(utilization of exts. from iris plants, Cimicifuga racemosa, and tectorigenin as estrogenlike organ-selective medicaments without uterotrophic effects)

REFERENCE COUNT: 3  
REFERENCE(S):  
(1) Anon; EP 0847755 A  
(2) Schaper & Bruemmer GMBH; DE 19652183 C 1998  
HCAPLUS  
(3) Tsumura Juntendo Inc; JP 63030417 A 1988 HCAPLUS

L27 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2001 ACS  
ACCESSION NUMBER: 1999:599509 HCAPLUS  
DOCUMENT NUMBER: 132:132284  
TITLE: Phytochemical and pharmacological studies of Dalbergia sissoo growing in Egypt  
AUTHOR(S): Sarg, Taha; Ateya, Abdel-Monem; Abdel-Ghani, Afaf;  
Badr, Wafaa; Shams, Gamal  
CORPORATE SOURCE: Department of Pharmacognosy, Faculty of Pharmacy,  
Zagazig University, Zagazig, Egypt  
SOURCE: Pharm. Biol. (Lisse, Neth.) (1999), 37(1), 54-62  
CODEN: PHBIFC; ISSN: 1388-0209  
PUBLISHER: Swets & Zeitlinger B.V.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB The isoflavones irisolidone, biochanin-A, muningin, tectorigenin, prunetin, genistein, sissotrin and prunetin-4-O-galactoside, the flavone norartocarpentin, and .beta.-amyrin, .beta.-sitosterol and stigmasterol were isolated and identified from the green branches of aerial parts of Dalbergia sissoo Roxb, using silica gel column chromatog. and spectral

anal. Also, 13 fatty acids were identified. The alc. ext. of the green branches of aerial parts showed a dose-dependent inhibitory effect on the motility of isolated rabbit duodenum, pronounced bronchodilation, as well as significant anti-inflammatory, antipyretic, analgesic, and estrogen-like activities. The plant ext. was well-tolerated by rats.

CC 1-12 (Pharmacology)

Section cross-reference(s): 11

IT **Estrogens**

RL: BSU (Biological study, unclassified); BIOL (Biological study) (-like activity; phytochem. and pharmacol. studies of *Dalbergia sissoo* growing in Egypt)

IT 57-10-3, Hexadecanoic acid, biological studies 57-11-4, Stearic acid, biological studies 60-33-3, Linoleic acid, biological studies 83-46-5, .beta.-Sitosterol 83-48-7, Stigmasterol 112-80-1, cis-9-Octadecenoic acid, biological studies 124-07-2, Octanoic acid, biological studies 143-07-7, Dodecanoic acid, biological studies 373-49-9, Palmitoleic acid 446-72-0, Genistein 479-83-4, Muningen 491-80-5, Biochanin-A 506-12-7, Heptadecanoic acid 506-26-3, .gamma.-Linolenic acid 520-30-9, Norartocarpentin 544-63-8, Tetradecanoic acid, biological studies 544-64-9, Myristoleic acid 548-77-6, Tectorigenin 552-59-0, Prunetin 559-70-6, .beta.-Amyrin 638-53-9, Tridecanoic acid 1002-84-2, Pentadecanoic acid 2345-17-7, Irisolidone 5928-26-7, Sissotrin 117007-27-9  
RL: BOC (Biological occurrence); BIOL (Biological study); OCCU (Occurrence)  
(phytochem. and pharmacol. studies of *Dalbergia sissoo* growing in Egypt)

REFERENCE COUNT: 32

REFERENCE(S):

- (1) Ahluwalia, V; Indian J Chem 1965, V3, P474 HCAPLUS
  - (6) Campbell, R; J Chem Soc (C) 1969, P1787 HCAPLUS
  - (12) Goda, Y; Chem Pharm Bull 1985, V33, P5606 HCAPLUS
  - (17) King, F; J Chem Soc 1952, P96 HCAPLUS
  - (23) Mukerjee, S; Tetrahedron 1971, V27, P799 HCAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

Flood 09/646,740

=> fil wpids

FILE 'WPIDS' ENTERED AT 15:04:27 ON 29 OCT 2001  
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE LAST UPDATED: 26 OCT 2001 <20011026/UP>  
MOST RECENT DERWENT UPDATE 200162 <200162/DW>  
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> Due to data production difficulties the latest DCR data  
loaded is for update 200160 <<<

>>> SDI'S MAY BE RUN ON EVERY UPDATE OR MONTHLY AS OF JUNE 2001.  
(EVERY UPDATE IS THE DEFAULT). FOR PRICING INFORMATION  
SEE HELP COST <<<

>>> FOR UP-TO-DATE INFORMATION ABOUT THE DERWENT CHEMISTRY  
RESOURCE, PLEASE VISIT  
[<<<](http://www.derwent.com/chemistryresource/index.html)

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES,  
SEE [<<<](http://www.derwent.com/covcodes.html)

=> d his

(FILE 'WPIDS' ENTERED AT 14:56:40 ON 29 OCT 2001)  
DEL HIS Y  
L1 0 S (BELAMCANDRA OR BELEMANDA) (W) CHINENIS  
L2 0 S (BELAMCANDRA OR BELEMANDA) (W) CHINENSIS  
L3 111 S IRIDACEAE OR IRIS (L) PLANT#  
L4 5 S TECTORIGENIN?  
L5 115 S L3 OR L4  
L6 26 S L5 AND B04/DC  
L7 6083 S ?ARTERIOSCLERO? OR ?ARTHEROSCLER?  
L8 357 S MENOPAUSE OR OSTEROPOROSIS OR HOT FLASH?  
L9 1 S L6 AND (L7 OR L8)  
L10 183 S CLIMACTER?  
L11 1 S L6 AND L10  
L12 9450 S CARDIOVAS?  
L13 3 S L12 AND L5  
L14 4 S L13 OR L11 OR L9  
L15 22 S L6 NOT L14

FILE 'WPIDS' ENTERED AT 15:04:27 ON 29 OCT 2001

=> d .wp 114 1-4;d bib 115 1-22

L14 ANSWER 1 OF 4 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
AN 2001-151164 [16] WPIDS  
DNC C2001-045110  
TI Breast promoter useful as therapeutic agent for preventing  
menopause and improving skin whitening and hair restoration in  
humans, contains processed roots or other parts of arrow root as active  
ingredient.  
DC B04 D21  
PA (KOBE-N) KOBE TENNENBUTSU KAGAKU KK  
CYC 1  
PI JP 2000302667 A 20001031 (200116)\* 9p  
ADT JP 2000302667 A JP 1999-115773 19990423  
PRAI JP 1999-115773 19990423  
AB JP2000302667 A UPAB: 20010323  
NOVELTY - A breast promoter contains processed roots or other parts of

arrow root as active ingredient.

ACTIVITY - Antipyretic; antiplasmodic; hypertensive; antidiarrheic.

No test details are given in the specification.

MECHANISM OF ACTION - None given.

USE - Useful as therapeutic agent for preventing **menopause** and for improving skin whitening and hair restoration in humans (claimed).

ADVANTAGE - The promoter effectively promotes skin whitening, breast development, prevents **menopause** and restores hair growth. The proliferation of mammary gland cells was tested in wister female rats by administering the liquid formulation containing arrow root for 1 week at an interval of 6 hours. The rats at the end of 50 days showed 10.2 vol/vol % increase and at the end of 80 days showed 15.1 vol/vol % increase in the proliferation of mammary cells.

Dwg.0/0

L14 ANSWER 2 OF 4 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
 AN 1999-561850 [47] WPIDS  
 DNC C1999-163781  
 TI Selective estrogenic plant extracts, e.g. from **iris** plants or containing **tectorigenin**, useful e.g. for treating atherosclerosis or osteoporosis.  
 DC B04  
 IN CHRISTOFFEL, V; JARRY, H; POPP, M; SPENGLER, B; WUTTKE, W  
 PA (PLAN-N) PLANTAMED ARZNEIMITTEL GMBH  
 CYC 87  
 PI WO 9947149 A1 19990923 (199947)\* DE 27p  
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL  
 OA PT SD SE SL SZ UG ZW  
 W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DK EE ES FI GB GD  
 GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV  
 MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT  
 UA UG US UZ VN YU ZA ZW  
 DE 19812204 A1 19991104 (199953)  
 AU 9931466 A 19991011 (200008)  
 BR 9908256 A 20001212 (200102)  
 EP 1064009 A1 20010103 (200102) DE  
 R: AT CH DE DK ES FR GB GR IT LI PT SE  
 CZ 2000002810 A3 20001213 (200103)  
 CN 1293575 A 20010502 (200143)  
 ADT WO 9947149 A1 WO 1999-EP1860 19990319; DE 19812204 A1 DE 1998-19812204  
 19980319; AU 9931466 A AU 1999-31466 19990319; BR 9908256 A BR 1999-8256  
 19990319, WO 1999-EP1860 19990319; EP 1064009 A1 EP 1999-913282 19990319,  
 WO 1999-EP1860 19990319; CZ 2000002810 A3 WO 1999-EP1860 19990319, CZ  
 2000-2810 19990319; CN 1293575 A CN 1999-804123 19990319  
 FDT AU 9931466 A Based on WO 9947149; BR 9908256 A Based on WO 9947149; EP  
 1064009 A1 Based on WO 9947149; CZ 2000002810 A3 Based on WO 9947149  
 PRAI DE 1998-19812204 19980319  
 AB WO 9947149 A UPAB: 19991116  
 NOVELTY - Organ-selective estrogenic medicaments comprise extracts of **iris** plants, extracts of *Cimifuga racemosa* or extracts containing (or enriched in) **tectorigenin** (TG) and/or TG glycoside.  
 DETAILED DESCRIPTION - The use of the following is claimed for the production of organ-selective estrogenic medicaments having no (or negligible) uterotrophic activity:  
 (i) extracts of **iris** plants (*Iridaceae*), specifically extracts of *Belamcanda sinensis*;  
 (ii) extracts of *Cimifuga racemosa*; or  
 (iii) extracts containing (or enriched in) TG of formula (I) and/or TG glycoside:  
 INDEPENDENT CLAIMS are included for the following:  
 (1) TG and/or its glycoside as a medicament; and  
 (2) plant extracts containing (or enriched in) TG and/or

its glycoside.

**ACTIVITY - Cardiovascular;** bone resorption inhibiting; climacteric.

**MECHANISM OF ACTION -** Selective estrogen receptor agonist. Ovariectomized rats were injected subcutaneously once daily with 62.5 mg of Cimicifuga racemosa extract (CR) or 8 micro g of estradiol (E2) for 7 days, using 5% Cremophor (RTM) as vehicle. Expression of mRNA for E2 receptor alpha in the preoptic region of the hypothalamus was approximately doubled (relative to vehicle-only treated controls) in both the CR and E2 treated groups.

**USE -** Organ-selective estrogenic medicaments are useful for the selective treatment and/or prophylaxis of **cardiovascular** disease (especially atherosclerosis), osteoporosis or **climacteric** disorders (especially for inhibiting or alleviating hot flushes) (all claimed).

**ADVANTAGE -** The extracts have beneficial estrogenic effects on the brain, ovaries, bones and vascular system, but no harmful side-effects on the uterus, vagina, breast tissue and liver.

Dwg.0/3

L14	ANSWER 3 OF 4	WPIDS COPYRIGHT 2001	DERWENT INFORMATION LTD
AN	1997-201883 [18]	WPIDS	
DNC	C1997-064503		
TI	Cell extracts from plant of <b>Iridaceae</b> family - used in compsns. for treating CNS, respiratory, skin, <b>cardiovascular</b> , immunological and urinary tract disorders.		
DC	B04 B05 D21		
IN	BRETON, L; DE, LACHARRIERE O; MARTIN, R		
PA	(OREA) L'OREAL SA		
CYC	12		
PI	WO 9709056 A1 19970313 (199718)* FR 55p		
	W: BR MX PL RU		
	EP 765668 A1 19970402 (199718) FR 27p		
	R: DE ES FR GB IT SE		
	FR 2738486 A1 19970314 (199720) 20p		
	FR 2738488 A1 19970314 (199720) 23p		
	CA 2185037 A 19970308 (199728) FR		
	JP 09124499 A 19970513 (199729) 22p		
	FR 2746647 A1 19971003 (199747) 33p		
	EP 765668 B1 19990317 (199915) FR		
	R: DE ES FR GB IT SE		
	DE 69601765 E 19990422 (199922)		
	BR 9610375 A 19990706 (199938)		
	ES 2132855 T3 19990816 (199939)		
	MX 9710479 A1 19980301 (200002)		
	JP 3093154 B2 20001003 (200051) 21p		
	RU 2169000 C2 20010620 (200144)		
ADT	WO 9709056 A1 WO 1996-FR1285 19960813; EP 765668 A1 EP 1996-401782 19960813; FR 2738486 A1 FR 1995-10486 19950907; FR 2738488 A1 FR 1995-10487 19950907; CA 2185037 A CA 1996-2185037 19960906; JP 09124499 A JP 1996-236986 19960906; FR 2746647 A1 FR 1996-3815 19960327; EP 765668 B1 EP 1996-401782 19960813; DE 69601765 E DE 1996-601765 19960813, EP 1996-401782 19960813; BR 9610375 A BR 1996-10375 19960813, WO 1996-FR1285 19960813; ES 2132855 T3 EP 1996-401782 19960813; MX 9710479 A1 MX 1997-10479 19971219; JP 3093154 B2 JP 1996-236986 19960906; RU 2169000 C2 WO 1996-FR1285 19960813, RU 1997-121856 19960813		
FDT	DE 69601765 E Based on EP 765668; BR 9610375 A Based on WO 9709056; ES 2132855 T3 Based on EP 765668; JP 3093154 B2 Previous Publ. JP 09124499; RU 2169000 C2 Based on WO 9709056		
PRAI	FR 1996-3815 19960327; FR 1995-10486 19950907; FR 1995-10487 19950907		
AB	WO 9709056 A UPAB: 19970502 Extract of cells (I) of at least 1 plant of the <b>Iridaceae</b>		

family, obtd. by in vitro culture, is new. Also claimed are compsns. comprising:(1) (I) and at least 1 prod. having an irritant effect, or(2) (I) and a cpd. which reduces the synthesis, liberation and/or activity of at least 1 inflammation mediator excluding steroidal and non-steroidal antiinflammatory agents.

USE - The extract is used in cosmetic or pharmaceutical compsns. for treating CNS disorders, respiratory disorders, allergic syndromes, inflammation, pain, gastrointestinal disorders, skin disorders, fibroses, collagen maturation disorders, **cardiovascular** disorders, vasospastic disorders, immunological disorders and/or urinary tract disorders. The compsns. are used for treating sensitive skins, e.g. for treating and/or preventing skin irritation, erythemas, sores, pain, inflammation and pruritus of the skin or mucous membranes. (I) can also be used as a CGRP and/or substance P antagonist and to treat disorders associated with an excess of the synthesis and/or liberation of CGRP and/or substance P. The compsns. are used for topical cosmetic treatment of the skin, hair and/or mucous membranes (all claimed).

Dwg.0/0

L14 ANSWER 4 OF 4 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
 AN 1997-156643 [15] WPIDS  
 DNC C1997-050232  
 TI Use of extracts of non-photosynthetic filamentous bacteria as substance P antagonists - in cosmetic and pharmaceutical compsns..  
 DC B04 D16 D21  
 IN AUBERT, L; BRETON, L; DE, LACHARRIERE O; LECLAIRE, J; MARTIN, R  
 PA (OREA) L'OREAL SA; (OREA) SOC L'OREAL SA  
 CYC 13  
 PI EP 761204 A1 19970312 (199715)\* FR 32p  
     R: DE ES FR GB IT SE  
     WO 9709032 A1 19970313 (199717) FR 61p  
     W: BR JP MX PL RU  
     FR 2738485 A1 19970314 (199720) 29p  
     CA 2185036 A 19970308 (199728) FR  
     FR 2746642 A1 19971003 (199747) 33p  
     FR 2746646 A1 19971003 (199747) 21p  
     EP 761204 B1 19980415 (199819) FR 44p  
     R: DE ES FR GB IT SE  
     DE 69600242 E 19980520 (199826)  
     US 5795574 A 19980818 (199840)  
     ES 2120274 T3 19981016 (199849)  
     JP 10511110 W 19981027 (199902) 69p  
     BR 9608500 A 19990706 (199938)  
     MX 9710478 A1 19980801 (200014)  
 ADT EP 761204 A1 EP 1996-401781 19960813; WO 9709032 A1 WO 1996-FR1284  
 19960813; FR 2738485 A1 FR 1995-10485 19950907; CA 2185036 A CA  
 1996-2185036 19960906; FR 2746642 A1 FR 1996-3818 19960327; FR 2746646 A1  
 FR 1996-3816 19960327; EP 761204 B1 EP 1996-401781 19960813; DE 69600242 E  
 DE 1996-600242 19960813, EP 1996-401781 19960813; US 5795574 A US  
 1996-711109 19960909; ES 2120274 T3 EP 1996-401781 19960813; JP 10511110 W  
 WO 1996-FR1284 19960813, JP 1997-510896 19960813; BR 9608500 A BR  
 1996-8500 19960813, WO 1996-FR1284 19960813; MX 9710478 A1 MX 1997-10478  
 19971219  
 FDT DE 69600242 E Based on EP 761204; ES 2120274 T3 Based on EP 761204; JP  
 10511110 W Based on WO 9709032; BR 9608500 A Based on WO 9709032  
 PRAI FR 1996-3818 19960327; FR 1995-10485 19950907; FR 1996-3816  
 19960327  
 AB EP 761204 A UPAB: 19970410  
 The following are claimed: (1) use of extracts (I) of non-photosynthetic filamentous bacteria as substance P antagonists in cosmetic compsns. or for prepns. of pharmaceutical compsns.; (2) cosmetic or pharmaceutical compsns. contg. (I) and prods. (II) with an irritant effect; (3) cosmetic or pharmaceutical compsns. contg. (I) and cell extracts (III) of plants of

the **Iridaceae** family; and (4) cosmetic or pharmaceutical compsns. contg. (I) and cpds. (IV) that reduce the synthesis, release and/or activity of inflammation mediators other than steroidal and nonsteroidal antiinflammatory agents.

USE - The compositions are useful for treating disorders associated with overproduction or excessive secretion of substance P, such as CNS disorders, respiratory disorders, allergies, inflammation, pain, gastrointestinal disorders, skin disorders, fibrosis, collagen maturation disorders, **cardiovascular** disorders, vasospasm, immunological disorders and/or disorders of the urinary tract; for treating sensitive skin; for preventing and/or combating skin and/or mucosal irritation (all claimed).

Dwg.0/0

- L15 ANSWER 1 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
AN 2001-453935 [49] WPIDS  
DNC C2001-137344  
TI Peroxidation oxygen elimination agent for use as cosmetics, comprises essence obtained from specific plants of Rubiaceae, **Iridaceae**, Guttiferae, Compositae, Moraceae, Labiateae, and Zingiberaceae.  
DC B04 D21  
PA (POKK) POLA CHEM IND INC  
CYC 1  
PI JP 2001131046 A 20010515 (200149)\* 7p  
ADT JP 2001131046 A JP 1999-313739 19991104  
PRAI JP 1999-313739 19991104
- L15 ANSWER 2 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
AN 2001-387141 [41] WPIDS  
DNC C2001-118104  
TI Protease inhibitor for improving and treating rough skin and other dermatological disorders such as keratonosis, comprises a plant extract of Pistacia, Lindera and/or Sapium.  
DC B04 D21  
PA (SHIS) SHISEIDO CO LTD  
CYC 1  
PI JP 2001122728 A 20010508 (200141)\* 9p  
ADT JP 2001122728 A JP 1999-298557 19991020  
PRAI JP 1999-298557 19991020
- L15 ANSWER 3 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
AN 2001-285640 [30] WPIDS  
DNC C2001-087500  
TI Skin external preparation for use as anti-aging cosmetics, comprises natural extract containing trehalose and oily substance, and has moisturizing effect.  
DC B04 D21  
PA (KAOS) KAO CORP  
CYC 1  
PI JP 2001039848 A 20010213 (200130)\* 9p  
ADT JP 2001039848 A JP 1999-212020 19990727  
PRAI JP 1999-212020 19990727
- L15 ANSWER 4 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
AN 2001-194007 [20] WPIDS  
DNC C2001-058530  
TI Serine protease inhibitor as skin external preparation and for treating dermatological disorders, comprises plants belonging to Rosaceae as the active ingredient.  
DC B04 D21

PA (SHIS) SHISEIDO CO LTD  
 CYC 1  
 PI JP 2000327555 A 20001128 (200120)\* 9p  
 ADT JP 2000327555 A JP 1999-141358 19990521  
 PRAI JP 1999-141358 19990521

L15 ANSWER 5 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
 AN 2001-051782 [07] WPIDS  
 DNC C2001-014396  
 TI External skin care composition comprises ceramide production-accelerating agent and film-forming polymer and enhances barrier function of skin and has excellent skin roughness-improving effect.  
 DC A96 B03 B04 D21  
 IN HORI, K; OHASHI, Y; SANO, T; TAKAGI, Y; YAMAKI, K  
 PA (KAOS) KAO CORP  
 CYC 26  
 PI EP 1051965 A2 20001115 (200107)\* EN 17p  
     R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT  
     RO SE SI  
     JP 2000319157 A 20001121 (200108) 7p  
 ADT EP 1051965 A2 EP 2000-109171 20000508; JP 2000319157 A JP 1999-128255  
     19990510  
 PRAI JP 1999-128255 19990510

L15 ANSWER 6 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
 AN 2000-194093 [17] WPIDS  
 DNC C2000-060070  
 TI Method of preparing a complex showing antiinflammatory, immunomodulating and antihypoxic effect.  
 DC B04  
 IN ASTAKHOVA, T V; MININA, S A; PRYAKHINA, N I  
 PA (SPET-R) ST PETERSBURG CHEM PHARM ACAD  
 CYC 1  
 PI RU 2123349 C1 19981220 (200017)\*  
 ADT RU 2123349 C1 RU 1997-106405 19970418  
 PRAI RU 1997-106405 19970418

L15 ANSWER 7 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
 AN 2000-137527 [13] WPIDS  
 DNC C2000-042325  
 TI Cosmetic and dermatological compositions made from plant materials, especially a synergistic mixture of liposoluble vegetable oils and liposoluble plant extracts.  
 DC B04 D21  
 PA (RAQU-I) RAQUET J  
 CYC 1  
 PI BE 1011858 A7 20000201 (200013)\* 49p  
 ADT BE 1011858 A7 BE 1998-249 19980401  
 PRAI BE 1998-249 19980401

L15 ANSWER 8 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
 AN 2000-092575 [08] WPIDS  
 DNC C2000-026898  
 TI Agent and cosmetics for inhibiting production of melanin.  
 DC B04 D21  
 PA (ICHIP) ICHIMARU PHARCÓS INC  
 CYC 1  
 PI JP 11335233 A 19991207 (200008)\* 17p  
 ADT JP 11335233 A JP 1998-158542 19980522  
 PRAI JP 1998-158542 19980522

L15 ANSWER 9 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
 AN 1998-581147 [49] WPIDS

DNC C1998-173691  
 TI After-shave cream composition having e.g. anti-inflammatory effect - comprises stearin, lanolin, glycerol, vegetable oil and ethanol, with yarrow, nettle, calendula, willowbark, burnet and bird cherry extracts.  
 DC B04 D21  
 IN DOLOTOVSKAYA, L Z; DOLOTOVSKII, I M; SHMELEV, A YA  
 PA (UFCO-R) UFA COSMETICS WKS  
 CYC 1  
 PI RU 2109506 C1 19980427 (199849)\* 6p  
 ADT RU 2109506 C1 RU 1995-105123 19950405  
 PRAI RU 1995-105123 19950405

L15 ANSWER 10 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
 AN 1998-469739 [41] WPIDS  
 DNC C1998-142439  
 TI De-pigmenting compositions for skin etc. - contains phenol and *Iridaceae* extract.  
 DC B04 B05 D21  
 IN BRETON, L  
 PA (OREA) L'OREAL SA  
 CYC 70  
 PI FR 2760191 A1 19980904 (199841)\* 19p  
 WO 9838978 A1 19980911 (199842) FR  
 RW: AT BE CH DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA  
 PT SD SE SZ UG ZW  
 W: AL AU BA BB BG BR CA CN CU CZ EE GE GH HU IL IS JP KP KR LC LK LR  
 LT LV MG MK MN MX NO NZ PL RO RU SG SI SK TR TT UA US UZ VN YU ZW  
 AU 9867360 A 19980922 (199908)  
 EP 1019017 A1 20000719 (200036) FR  
 R: DE ES FR GB IT  
 CN 1253495 A 20000517 (200041)  
 JP 2000510165 W 20000808 (200043) 20p  
 KR 2000075870 A 20001226 (200134)  
 ADT FR 2760191 A1 FR 1997-2504 19970303; WO 9838978 A1 WO 1998-FR402 19980302;  
 AU 9867360 A AU 1998-67360 19980302; EP 1019017 A1 EP 1998-912574  
 19980302, WO 1998-FR402 19980302; CN 1253495 A CN 1998-804617 19980302; JP  
 2000510165 W JP 1998-538224 19980302, WO 1998-FR402 19980302; KR  
 2000075870 A WO 1998-FR402 19980302, KR 1999-707949 19990901  
 FDT AU 9867360 A Based on WO 9838978; EP 1019017 A1 Based on WO 9838978; JP  
 2000510165 W Based on WO 9838978; KR 2000075870 A Based on WO 9838978  
 PRAI FR 1997-2504 19970303

L15 ANSWER 11 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
 AN 1998-393405 [34] WPIDS  
 DNC C1998-119258  
 TI Antiinflammatory analgesic plaster for treating arthritis, etc. - comprises indomethacin and extracted substances and extract compositions of rhizoma of Iris germanica Lam., I. florentia L. and I. pallida L. (*Iridaceae*).  
 DC B02 B04 B07  
 PA (TAIS) TAISHO PHARM CO LTD  
 CYC 1  
 PI JP 10158186 A 19980616 (199834)\* 4p  
 ADT JP 10158186 A JP 1996-319144 19961129  
 PRAI JP 1996-319144 19961129

L15 ANSWER 12 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
 AN 1998-090031 [09] WPIDS  
 DNN N1998-071373 DNC C1998-030496  
 TI New lectin produced by expression of plant of *Iridaceae* - used in separation or purification of polysaccharide(s) or glyco-protein(s) or as antiviral agent or growth inhibitor against fungi, etc..  
 DC B04 C03 S03

PA (TKAK) TAYCA CORP  
 CYC 1  
 PI JP 09124694 A 19970513 (199809)\* 7p  
 ADT JP 09124694 A JP 1995-305028 19951030  
 PRAI JP 1995-305028 19951030

L15 ANSWER 13 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
 AN 1998-059103 [06] WPIDS  
 DNC C1998-020387  
 TI Belamcanda chinensis L. extracts, cell activating agent contg.  
 alpha-hydroxy acid, and their usage - used for bathing compositions or  
 skin external compositions.  
 DC B04 D21  
 PA (ICHIP) ICHIMARU PHARCOS INC  
 CYC 1  
 PI JP 09301883 A 19971125 (199806)\* 13p  
 ADT JP 09301883 A JP 1996-146822 19960515  
 PRAI JP 1996-146822 19960515

L15 ANSWER 14 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
 AN 1997-460242 [43] WPIDS  
 DNC C1997-147046  
 TI Skin or hair treatment composition - contains undifferentiated Ginkgo  
 biloba cells or their extracts, and is free of irritant and/or allergenic  
 components.  
 DC B04 D21  
 IN MARTIN, R; MELLUL, M  
 PA (OREA) L'OREAL SA  
 CYC 1  
 PI FR 2744915 A1 19970822 (199743)\* 24p  
 ADT FR 2744915 A1 FR 1996-1969 19960216  
 PRAI FR 1996-1969 19960216

L15 ANSWER 15 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
 AN 1997-161403 [15] WPIDS  
 DNC C1997-051681  
 TI An external compsn for fair skin for e g sunburn treatment - comprises  
 solvent extract of **Iridaceae** family.  
 DC B04 D21  
 PA (SHIS) SHISEIDO CO LTD  
 CYC 1  
 PI JP 09030954 A 19970204 (199715)\* 10p  
 ADT JP 09030954 A JP 1996-84750 19960313  
 PRAI JP 1995-142680 19950517

L15 ANSWER 16 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
 AN 1995-228635 [30] WPIDS  
 DNC C1995-105333  
 TI Testosterone 5-alpha reductase inhibitor contg. extract of Belamcanda  
 chinensis L. - is used in prepns. for treatment of seborrhea, acne  
 vulgaris and male alopecia.  
 DC B04 D16 D21  
 PA (ICHIP) ICHIMARU PHARCOS INC  
 CYC 1  
 PI JP 07138181 A 19950530 (199530)\* 6p  
 ADT JP 07138181 A JP 1993-309859 19931115  
 PRAI JP 1993-309859 19931115

L15 ANSWER 17 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
 AN 1995-228633 [30] WPIDS  
 DNC C1995-105331  
 TI Cell activator for preventing skin ageing - comprises Belamcanda chinensis  
 L., belonging to **Iridaceae** or its dried roots extracts with e.g.

water.

DC **B04 D21**

PA (ICHP) ICHIMARU PHARCOS INC

CYC 1

PI JP 07138179 A 19950530 (199530)\* 7p

ADT JP 07138179 A JP 1993-309858 19931115

PRAI JP 1993-309858 19931115

L15 ANSWER 18 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 1989-008908 [02] WPIDS

DNC C1989-004122

TI Herbal compsn. for treating skin and scalp disorders - e.g. psoriasis and hair loss, is infusion of lavender, mint, sage, etc. in vinegar.

DC **B04 D21**

IN PASINI, I

PA (IRIS-N) IRIS SAS DI SALVIOL

CYC 14

PI EP 297640 A 19890104 (198902)\* EN 5p  
 R: AT BE CH DE ES FR GB GR LI LU NL SE  
 US 4855131 A 19890808 (198939) 3p  
 IT 1206794 B 19890503 (199131)  
 EP 297640 B 19910828 (199135)  
 R: AT BE CH DE ES FR GB GR LI LU NL SE  
 DE 3864464 G 19911002 (199141)

ADT EP 297640 A EP 1988-201129 19880604; US 4855131 A US 1988-203910 19880608

PRAI IT 1987-21115 19870630

L15 ANSWER 19 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 1988-296436 [42] WPIDS

DNC C1988-131535

TI Agent for treatment of peptic ulcers - contains alcohol-soluble fraction of ether-insol. fraction of alcohol extract of Iris root.

DC **B04**

PA (ZERI) ZERIA SHINYAKU KOGYO KK

CYC 1

PI JP 63216824 A 19880909 (198842)\* 6p

ADT JP 63216824 A JP 1987-50495 19870305

PRAI JP 1987-50495 19870305

L15 ANSWER 20 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 1988-268231 [38] WPIDS

DNC C1988-119536

TI Anti-peptic ulcer drug - is extracted from roots of iris using alcohol and further extracted using ether, giving solubility in tri chloro-methane etc..

DC **B04**

PA (ZERI) ZERIA SHINYAKU KOGYO KK

CYC 1

PI JP 63196522 A 19880815 (198838)\* 7p

ADT JP 63196522 A JP 1987-29237 19870210

PRAI JP 1987-29237 19870210

L15 ANSWER 21 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 1985-248004 [40] WPIDS

DNC C1985-107742

TI Embinin prepns. by extn. and column chromatography - involves using over-ground part of iris as raw material and alkaline treatment.

DC **B04 D16**

IN BLINOVA, K F; GLYZIN, V I; PRYAKHINA, N I

PA (LECH-R) LENGD CHEM PHARM

CYC 1

PI SU 1146049 A 19850323 (198540)\* 2p

ADT SU 1146049 A SU 1983-3549586 19830207

Flood 09/646,740

PRAI SU 1983-3549586 19830207

L15 ANSWER 22 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
AN 1985-070439 [12] WPIDS  
DNC C1985-030444  
TI Anticancer flower of cancer - used to treat cancer of digestive organs.  
DC **B04**  
PA (WANA-I) WATANABE K  
CYC 1  
PI JP 57007422 A 19820114 (198512)\* 3p  
ADT JP 57007422 A JP 1980-81111 19800614  
PRAI JP 1980-81111 19800614

=> d his

(FILE 'WPIDS' ENTERED AT 14:56:40 ON 29 OCT 2001)

DEL HIS Y

L1 0 S (BELAMCANDRA OR BELEMANDA) (W) CHINENIS  
 L2 0 S (BELAMCANDRA OR BELEMANDA) (W) CHINENSIS  
 L3 111 S IRIDACEAE OR IRIS (L) PLANT#  
 L4 5 S TECTORIGENIN?  
 L5 115 S L3 OR L4  
 L6 26 S L5 AND B04/DC  
 L7 6083 S ?ARTERIOSCLERO? OR ?ARTHEROSCLER?  
 L8 357 S MENOPAUSE OR OSTEROPOROSIS OR HOT FLASH?  
 L9 1 S L6 AND (L7 OR L8)  
 L10 183 S CLIMACTER?  
 L11 1 S L6 AND L10  
 L12 9450 S CARDIOVAS?  
 L13 3 S L12 AND L5  
 L14 4 S L13 OR L11 OR L9  
 L15 22 S L6 NOT L14

FILE 'WPIDS' ENTERED AT 15:04:27 ON 29 OCT 2001

L16 7 S IRIS## AND (L7 OR L8 OR L10 OR L12)  
 L17 6 S L16 NOT (L14 OR L15)

=> d .wp 1-6

L17 ANSWER 1 OF 6 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
 AN 2000-237524 [20] WPIDS  
 DNC C2000-072211  
 TI Inhibition of angiogenesis and endothelial cell proliferation in angiogenesis-related diseases e.g. macular degeneration and uterine vascularization by administering melanin.  
 DC B04  
 IN D'AMATO, R J  
 PA (CHIL-N) CHILDRENS MEDICAL CENT  
 CYC 88  
 PI WO 2000010507 A2 20000302 (200020)\* EN 30P  
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL  
 PT SD SE SL SZ UG ZW  
 W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES  
 FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS  
 LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ  
 TM TR TT UA UG US UZ VN YU ZA ZW  
 AU 9963132 A 20000314 (200031)  
 EP 1119252 A2 20010801 (200144) EN  
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT  
 RO SE SI  
 ADT WO 2000010507 A2 WO 1999-US19026 19990820; AU 9963132 A AU 1999-63132  
 19990820; EP 1119252 A2 EP 1999-967818 19990820, WO 1999-US19026 19990820  
 FDT AU 9963132 A Based on WO 200010507; EP 1119252 A2 Based on WO 200010507  
 PRAI US 1998-97385 19980821  
 AB WO 200010507 A UPAB: 20000426  
 NOVELTY - Inhibiting angiogenesis in an individual by administering melanin, is new.  
 DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:  
 (1) inhibiting angiogenesis in an individual by administering a melanin-promoting compound; and  
 (2) treating macular degeneration in an individual by administering melanin or a melanin-promoting compound.  
 ACTIVITY - Antiangiogenic; anti-macular degeneration; antidiabetic; immunosuppressive; keratolytic; dermatological; antibacterial; vulnerary;

antiulcer; cytostatic; anti-HIV; antirheumatic; antiarthritic; antiinflammatory; tranquilizer; vasotropic; antiarteriosclerotic; antipsoriatic; cerebroprotective; gynecological.

Pellets of bovine fibroblast growth factor (bFGF) were placed in corneas of mice pigmented C57b16, substrain C57b16J/Tyr-c albino (mutation in tyrosinase), 129J (normally albino) and pigmented 129/SV+p+Tyr-c. None of the pigmented mice of C57b16 showed iris vessel growth and bleeding while the growth was 7/8, 17/18 and 2/17 respectively. The growth % was 0, 88, 94 and 12 respectively.

MECHANISM OF ACTION - In vitro endothelial cell proliferation inhibitor; angiogenesis inhibitor.

USE - To treat angiogenesis-related diseases in both humans and animals e.g. diabetic retinopathy; corneal neovascularization e.g. epidemic keratoconjunctivitis, atopic keratitis; retinal/choroidal neovascularization e.g. macular degeneration, Lyme's disease, toxoplasmosis; rheumatoid arthritis; chronic inflammation e.g. ulcerative colitis, Crohn's disease; atherosclerosis; hemangioma; solid tumor formation; hematopoiesis; ovulation; menstruation and placentation. Also as birth control agent to prevent or reduce uterine vascularization for embryo implantation. Addition of 38 mg melanin to the cornea of albino mice decreases the ability of bFGF pellets to induce angiogenesis by 24% when compared to non-melanin controls.

ADVANTAGE - The composition provides a therapy for macular degeneration that has minimal side effects.

Dwg.0/0

L17 ANSWER 2 OF 6 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
 AN 1998-272116 [24] WPIDS  
 DNC C1998-084957  
 TI New aryl-amino compounds mediating the effect of somatostatin agonists or antagonists - useful for treating medical disorders related to binding to human somatostatin receptor subtype(s).  
 DC B03 B05  
 IN ANKERSEN, M; CRIDER, A M; DORWALD, F Z; STIDSEN, C E; DOERWALD, F Z;  
 CARSTEN, E S; ZARAGOZA, D F  
 PA (NOVO) NOVO-NORDISK AS  
 CYC 80  
 PI WO 9818786 A1 19980507 (199824)\* EN 45p  
 RW: AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL OA PT  
 SD SE SZ UG ZW  
 W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE  
 GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW  
 MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU  
 ZW  
 ZA 9709701 A 19980729 (199835) 40p  
 AU 9747724 A 19980522 (199840)  
 EP 937065 A1 19990825 (199939) EN  
 R: AL AT BE CH DE DK ES FI FR GB GR IE IT LI LT LU LV NL PT RO SE SI  
 US 6020349 A 20000201 (200013)  
 US 6083960 A 20000704 (200036)  
 JP 2001502712 W 20010227 (200115) 48p  
 ADT WO 9818786 A1 WO 1997-DK488 19971029; ZA 9709701 A ZA 1997-9701 19971029;  
 AU 9747724 A AU 1997-47724 19971029; EP 937065 A1 EP 1997-910268 19971029,  
 WO 1997-DK488 19971029; US 6020349 A US 1997-962098 19971031; US 6083960 A  
 Div ex US 1997-962098 19971031, US 1999-397355 19990916; JP 2001502712 W  
 WO 1997-DK488 19971029, JP 1998-519947 19971029  
 FDT AU 9747724 A Based on WO 9818786; EP 937065 A1 Based on WO 9818786; US  
 6083960 A Div ex US 6020349; JP 2001502712 W Based on WO 9818786  
 PRAI DK 1996-1216 19961031  
 AB WO 9818786 A UPAB: 19981021  
 Compounds of formula (I), and their salts are new. A = aryl optionally substituted with one or more halo, amino, hydroxyl, nitro, 1-6C alkyl, 1-6C alkoxy or aryl; B = aryl optionally substituted with one or more

halo, amino, hydroxyl, 1-6C alkyl, 1-6C alkoxy or aryl; m = 0-6; n = 0-3; Y = valence bond or group of formula (i); q and s = 0-5 and q + s = 1-5; R1 = H or 1-6C alkyl optionally substituted with halo, amino, hydroxy, 1-6C alkoxy or aryl; E = N(R2)-D or group of formula (ii); p = 0-4; r = 1-6; Z = N or CH; D = aryl optionally substituted with one or more halo, amino, hydroxyl, 1-6C alkyl, 1-6C alkoxy, piperidinyl or aryl; R2 = H or 1-6C alkyl optionally substituted with halo, amino, hydroxy, 1-6C alkoxy or aryl; with the proviso that if m = 0 then Y is not a valence bond.

USE - (I) are useful prophylactically or therapeutically for mediating the biological effect of somatostatin agonists or antagonists. Compositions are administered by oral, nasal, buccal, transdermal, pulmonal or parenteral routes. (I) are useful in treatment of airway disorders such as asthma, as anti-diarrhoeals and for the modulation of gastric acid secretion, for treatment of diseases associated with regulation of sleep and wakefulness and for the treatment of narcolepsy and attention deficit disorders, for use as non-amphetamine-like stimulants or as sedatives, for the treatment of eating disorders (e.g. anorexia or bulimia) by virtue of their appetite regulating properties, for treatment of conditions associated with epilepsy, for treatment of motion sickness and vertigo and for the treatment of dementia and Alzheimer disease. (I) are useful for modulation of glucagon and insulin secretion to treat type I and type II diabetes, treatment of CFS, inhibition of cell proliferation and growth to treat various endocrine and exocrine tumours, modulation of growth hormone secretion to treat dwarfism, acromegaly and other growth abnormalities, modulation of immune responses to treat autoimmune diseases, rheumatoid arthritis and other inflammations, modulation of neuronal activity to treat diseases related to the central nervous system, i.e. pain, anxiety, memory disorders, affective disorders and Alzheimer's disease, modulation of intestinal water uptake to treat congestion and diarrhoea, inhibition of arterial smooth muscle cell proliferation to treat restenosis and arteriosclerosis, inhibition of airway mucous secretion to treat asthma and mucoviscidosis, modulation of lipid metabolism and regulation of energy balance to treat obesity, inhibition of acid secretion to treat ulcer, inhibition of pancreatic secretions to treat acute pancreatitis, for the treatment of a disease associated with an adverse condition in the retina and/or iris/ciliary body of a mammal, such conditions being high intraocular pressure (IOP) and/or deep ocular infections, e.g. glaucoma, stromal keratitis, iritis, retinitis, cataract and conjunctivitis. (I) are useful for development of pharmaceutical, therapeutic and diagnostic techniques.

Dwg.0/0

L17 ANSWER 3 OF 6 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
 AN 1995-344451 [44] WPIDS  
 DNC C1995-151377  
 TI Treating glaucoma or ocular hypertension - using new or known thio prostaglandin cpds., reducing intraocular pressure without irritation.  
 DC B05  
 IN BITO, L Z; RESUL, B; STJERN SCHANTZ, J; STJERN SCHANTZ, J W  
 PA (PHAA) PHARMACIA AB; (KABI) KABI PHARMACIA AB  
 CYC 58  
 PI WO 9525520 A1 19950928 (199544)\* EN 27p  
 RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE  
 W: AM AU BB BG BR BY CA CN CZ EE FI GE HU JP KE KG KP KR KZ LK LR LT  
 LV MD MG MN MW MX NO NZ PL RO RU SD SI SK TJ TT UA UZ VN  
 AU 9521546 A 19951009 (199603)  
 US 5516796 A 19960514 (199625) 7p  
 ADT WO 9525520 A1 WO 1995-SE316 19950324; AU 9521546 A AU 1995-21546 19950324;  
 US 5516796 A US 1994-217515 19940324  
 FDT AU 9521546 A Based on WO 9525520  
 PRAI US 1994-217515 19940324  
 AB WO 9525520 A UPAB: 19951109

A pharmaceutical compsn. contains a thioprostaglandin cpd. of formula (I) in an ophthalmologically acceptable carrier. X = 5-7 membered ring; R1 = (a) opt. branched alkyl or alkene chain; (b) cycloalkyl or cycloalkyl having 6-7 ring C; heteroatom subst. cycloalkyl or cycloalkenyl having 3-7 ring atoms; aryl; or heteroaryl; (c) opt. branched alkyl or alkene chain interrupted by or incorporating one or more heteroatoms selected from O, S and N, or a gp. (a) or (b) which is subst. by or incorporates a ring structure as in (b); or (d) a gp. (c) or (d) (sic) in which the ring structure is further subst. by one or more of 1-5C alkyl, 1-3C aliphatic acylamino, NO<sub>2</sub>, halo and aryl.

USE - As well as the claimed uses for treating glaucoma and ocular hypertension, (I) may be active on other organ systems (e.g. the gastrointestinal and **cardiovascular** systems). Specifically (Ia) and (Ib) stimulate the rate fundus, cat or bovine **iris** sphincter and the circular (but not longitudinal) prepn. of guinea pig ileum, and affect platelet aggregation.

ADVANTAGE - (I) provide maximal lowering of intraocular pressure (IOP), while causing minimal side-effects such as ocular irritation.  
Dwg.0/0

L17 ANSWER 4 OF 6 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
 AN 1991-222645 [30] WPIDS  
 DNC C1991-096668  
 TI Use of inositol phosphate derivs. - for treating tissue damage, diabetes and its complications, disorders related to transplantation, **cardiovascular** diseases, etc..  
 DC B05  
 IN SIR, N; SIREN, M  
 PA (PEST) PERSTORP AB  
 CYC 17  
 PI WO 9109601 A 19910711 (199130)\*  
 AU 9169700 A 19910724 (199143)  
 EP 505452 A1 19920930 (199240) EN 18p  
 GB 2255505 A 19921111 (199246) 18p  
 JP 05502864 W 19930520 (199325) 7p  
 US 5342832 A 19940830 (199434) 4p  
 EP 505452 B1 19960619 (199629) EN 6p  
 R: AT BE CH DE DK ES FR GB GR IT LI LU NL SE  
 DE 69027540 E 19960725 (199635)  
 ES 2090303 T3 19961016 (199647)  
 ADT EP 505452 A1 WO 1990-SE842 19901218, EP 1991-901333 19901218; GB 2255505 A  
 WO 1990-SE842 19901218, GB 1992-12113 19920608; JP 05502864 W WO  
 1990-SE842 19901218, JP 1991-501719 19901218; US 5342832 A WO 1990-SE842  
 19901218, US 1992-862564 19920821; EP 505452 B1 WO 1990-SE842 19901218, EP  
 1991-901333 19901218; DE 69027540 E DE 1990-627540 19901218, WO 1990-SE842  
 19901218, EP 1991-901333 19901218; ES 2090303 T3 EP 1991-901333 19901218  
 FDT EP 505452 A1 Based on WO 9109601; GB 2255505 A Based on WO 9109601; JP  
 05502864 W Based on WO 9109601; US 5342832 A Based on WO 9109601; EP  
 505452 B1 Based on WO 9109601; DE 69027540 E Based on EP 505452, Based on  
 WO 9109601; ES 2090303 T3 Based on EP 505452  
 PRAI SE 1989-4355 19891221  
 AB WO 9109601 A UPAB: 19930928  
 Use of inositolphosphate derivs. of formula C<sub>6</sub>H<sub>6</sub>(OH)<sub>6-n</sub>(OPO<sub>3</sub>H<sub>2</sub>)<sub>n</sub> (I) (n = 1 or 2) for preventing, alleviating or combating tissue damage such as oedema formation and vascular linkage, diabetes or its complications such as osteoporosis and bone erosion, disorders related to transplantation such as rejection, abnormal levels of lipoproteins, **cardiovascular** diseases, haemorrhage and inflammatory conditions is claimed.  
 The use of 16 cpds. is specifically claimed, e.g. myo-inositol-monophosphate and scylloinositol-bis-phosphate. Also claimed is a compsn. comprising (I) and a carrier, excipient or additive. The use is 0.1-1000 (0.1-200) mg/kg/day.  
 USE/ADVANTAGE - (I) are also used for treating damage to cell

membranes, metal intoxication, conditions of ischaemia and reperfusion, conditions of shock, conditions related to vasculitis, dermatitis, gastrointestinal diseases, synovitis, periodontal and cerebral diseases, autoimmune diseases, eye diseases, light and oxygen induced diseases or damage and skin damage. (I) improves stabilisation, decreases deformation and improves the function of different cells. (I) also regulates membrane fluidity, the incorporation of cell membrane components and the prodn. incorporation and balance between different phospholipids.

0/0

L17 ANSWER 5 OF 6 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
 AN 1990-348222 [46] WPIDS  
 DNN N1990-266074  
 TI Monitoring device for body functions e.g. during anaesthesia - comprises scleral contact lens with light source and light receiver to illuminate retina.  
 DC P31 S03 S05  
 IN GLYNN, C J; HILL, A R  
 PA (GLYN-I) GLYNN C J; (HILL-I) HILL A R  
 CYC 17  
 PI WO 9012534 A 19901101 (199046)\* 40p  
     RW: AT BE CH DE DK ES FR GB IT LU NL SE  
     W: AU CA GB JP US  
 AU 9055379 A 19901116 (199107)  
 EP 471725 A 19920226 (199209)  
     R: AT BE CH DE ES FR GB IT LI NL SE  
 GB 2248297 A 19920401 (199214) 1p  
 JP 04504670 W 19920820 (199240) 11p  
 GB 2265003 A 19930915 (199337) 36p  
 GB 2248297 B 19931124 (199347) 2p  
 GB 2265003 B 19931201 (199348) 2p  
 US 5297554 A 19940329 (199412) 15p  
 AU 9453038 A 19940303 (199414)  
 AU 646804 B 19940310 (199415)  
 AU 655570 B 19941222 (199507)  
 EP 686372 A1 19951213 (199603) EN 16p  
     R: AT CH DE ES FR IT LI NL  
 EP 471725 B1 19951227 (199605) EN 20p  
     R: AT BE CH DE DK ES FR GB IT LI NL SE  
 DE 69024490 E 19960208 (199611)  
 ES 2084029 T3 19960501 (199625)  
 CA 2051419 C 20000118 (200024) EN  
 EP 686372 B1 20010117 (200105) EN  
     R: AT CH DE ES FR IT LI NL  
 DE 69033694 E 20010222 (200118)  
 ES 2156170 T3 20010616 (200141)  
 ADT EP 471725 A EP 1990-907221 19900426; GB 2248297 A GB 1990-21230 19900426;  
 JP 04504670 W JP 1990-506667 19900426, WO 1990-GB648 19900426; GB 2265003  
 A Derived from GB 1991-21230 19900426, GB 1993-8630 19930426; GB 2248297 B  
 WO 1990-GB648 19900426, GB 1991-21230 19900426; GB 2265003 B Derived from  
 GB 1991-21230 19900426, GB 1993-8630 19930426; US 5297554 A WO 1990-GB648  
 19900426, US 1991-768645 19910927; AU 9453038 A AU 1994-53038 19940106,  
 Div ex AU 1990-55379 ; AU 646804 B AU 1990-55379 19900426; AU  
 655570 B AU 1994-53038 19940106, Div ex AU 1990-55379 ; EP 686372  
 A1 EP 1995-108792 19900426; EP 471725 B1 EP 1990-907221 19900426, WO  
 1990-GB648 19900426; DE 69024490 E DE 1990-624490 19900426, EP 1990-907221  
 19900426, WO 1990-GB648 19900426; ES 2084029 T3 EP 1990-907221 19900426;  
 CA 2051419 C CA 1990-2051419 19900426, WO 1990-GB648 19900426; EP 686372  
 B1 Div ex EP 1990-907221 19900426, EP 1995-108792 19900426; DE 69033694 E  
 DE 1990-633694 19900426, EP 1995-108792 19900426; ES 2156170 T3 EP  
 1995-108792 19900426  
 FDT JP 04504670 W Based on WO 9012534; GB 2248297 B Based on WO 9012534; US  
 5297554 A Based on WO 9012534; AU 646804 B Previous Publ. AU 9055379,

Based on WO 9012534; AU 655570 B Previous Publ. AU 9453038; EP 471725 B1  
Based on WO 9012534; DE 69024490 E Based on EP 471725, Based on WO  
9012534; ES 2084029 T3 Based on EP 471725; CA 2051419 C Based on WO  
9012534; EP 686372 B1 Div ex EP 471725; DE 69033694 E Based on EP 686372;  
ES 2156170 T3 Based on EP 686372

PRAI GB 1989-9491 19890426

AB WO 9012534 A UPAB: 19930928

The device comprises a scleral contact lens (1) for locating and supporting at least one discrete light source e.g. an optical fibre (9) or a light emitting diode, and at least one discrete light receiver e.g. an optical fibre (10) or a photodetector, mounted within a carrier (6) on the scleral contact lens. The arrangement is such that, in use, light from the light source is directed through the contact lens towards the eye to illuminate the retina of the eye independently of pupil size.

The light receiver is positioned to receive light returning through the lens directly from that portion of the retina which is illuminated directly by the light input to maximise the quantity of light received.

USE - Non-invasive, real-time monitoring of cardiovascular, respiratory neuromuscular and other bodily functions.

8/11

L17 ANSWER 6 OF 6 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 1980-74836C [42] WPIDS

TI Non-alcoholic tonic drink - contg. sugar, citric and acetic acids, eleuterococcus extract, vanillin, infusions of lemon, tea, tarragon and iris root, and water.

DC D13

IN BLIADZE, M V; ERISTAVI, L I; MIKELADZE, G G

PA (TBIL-R) TBILISI MEDICINE INST; (UYTB-R) TBILISI UNIV

CYC 1

PI SU 719595 A 19800310 (198042)\*

PRAI SU 1978-2566324 19780109

AB SU 719595 A UPAB: 19930902

Non-alcoholic tonic drink contains (in wt.%): sugar 9.1-9.5, citric acid 0.12-0.16, eleuterococcus extract 0.05-0.15, lemon tea infusion 2.0-2.6, estrogen infusion 0.7-1.2, iris root infusion 0.03-0.07, vanilin 0.008-0.018, acetic acid 2.2-2.4; the balance is water. The drink has emerald colour, agreeable taste and aroma.

The combination of caffeine (contained in the lemon-tea infusion) with eleuterosides (present in the eleuterococcus extract) exerts distinct tonic effect. The drink contains vitamin P (catechins of tea and cytrus), C, K, B, B2 and PP, and biologically active ethereal oils. The vitamin P reduces the brittleness of blood vessels, thus preventing arteriosclerosis.

Flood 09/646,740

=> fil medline

FILE 'MEDLINE' ENTERED AT 07:58:24 ON 01 NOV 2001

FILE LAST UPDATED: 30 OCT 2001 (20011030/UP). FILE COVERS 1958 TO DATE.

On April 22, 2001, MEDLINE was reloaded. See HELP RLOAD for details.

MEDLINE now contains IN-PROCESS records. See HELP CONTENT for details.

MEDLINE is now updated 4 times per week. A new current-awareness alert frequency (EVERYUPDATE) is available. See HELP UPDATE for more information.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2001 vocabulary. Enter HELP THESAURUS for details.

The OLDMEDLINE file segment now contains data from 1958 through 1965. Enter HELP CONTENT for details.

Left, right, and simultaneous left and right truncation are available in the Basic Index. See HELP SFIELDS for details.

THIS FILE CONTAINS CAS REGISTRY NUMBERS FOR EASY AND ACCURATE SUBSTANCE IDENTIFICATION.

=> d his

(FILE 'MEDLINE' ENTERED AT 07:44:54 ON 01 NOV 2001)

DEL HIS Y

L1	77134 S PLANTS, MEDICINAL+NT/CT OR PLANT EXTRACTS+NT/CT
L2	52 S L1 AND (IRIS OR IRISES OR IRIDACE?)
L3	12 S L1 AND TECTORIGENIN?
L4	61 S L2 OR L3
L5	0 S (BELAMCANDA OR BELAMCANDRA) (2W) SINENSIS
L6	11 S BELAMCANDA
L7	65 S L6 OR L4 E OSTEOPOROSIS/CT E E3+ALL E ARTERIOSCLEROSIS/CT E E3+ALL E E2+ALL E CLIMACTERIC/CT E E3+ALL
L8	0 S L7 AND (C14./CT OR OSTEOPOROSIS+NT/CT OR HEART DISEASE+NT/CT)
L9	0 S L7 AND (C14./CT OR OSTEOPOROSIS+NT/CT OR CLIMACTERIC+NT/CT)
L10	0 S L7 AND ESTROGEN?

FILE 'MEDLINE' ENTERED AT 07:58:24 ON 01 NOV 2001

=> fil biosis  
FILE 'BIOSIS' ENTERED AT 08:05:04 ON 01 NOV 2001  
COPYRIGHT (C) 2001 BIOSIS(R)

FILE COVERS 1969 TO DATE.  
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT  
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 31 October 2001 (20011031/ED)

The BIOSIS file has been reloaded. Enter HELP RLOAD and HELP REINDEXING  
for details.

=> d his

(FILE 'MEDLINE' ENTERED AT 07:58:24 ON 01 NOV 2001)  
DEL HIS Y

FILE 'BIOSIS' ENTERED AT 07:58:54 ON 01 NOV 2001  
L1 3741 S IRIDACEAE? OR IRIS (4A) (PLANT# OR EXTRAC?)  
L2 49 S TECTORIGENIN?  
L3 53 S BELAMCANDA OR BELAMCANDRA  
L4 3777 S L1 OR L2 OR L3  
L5 302539 S EXTRACT? OR EXT#  
L6 243 S L4 AND L5  
L7 54153 S ARTERIOSCLE? OR ATHEROSCLER?  
L8 1 S L6 AND L7  
L9 166804 S (CARDIOVASCULAR OR HEART?) (4A) DISEASE?  
L10 0 S L9 AND L6  
L11 24692 S OSTEOPOROSIS? OR MENOPAUSE OR CLIMACTERIC  
L12 0 S L6 AND L11  
L13 2 S L4 AND L7  
L14 0 S L4 AND L9  
L15 3 S L4 AND L11  
L16 5 S L8 OR L13 OR L15

FILE 'BIOSIS' ENTERED AT 08:05:04 ON 01 NOV 2001

=> d bib ab it 1-5

L16 ANSWER 1 OF 5 BIOSIS COPYRIGHT 2001 BIOSIS  
AN 1995:484679 BIOSIS  
DN PREV199598498979  
TI Senescence and ethylene production of cut gladiolus.  
AU Hwang, Moon Joo; Kwon, Hye Jin; Kim, Ki Sun; Lee, Seung Koo  
CS Dep. Horticulture, Seoul National University, Suwon 441-744 South Korea  
SO Journal of the Korean Society for Horticultural Science, (1995) Vol. 36,  
No. 4, pp. 555-559.  
ISSN: 0253-6498.  
DT Article  
LA Korean  
SL Korean; English  
AB This study was conducted 1) to investigate the postharvest physiology and  
2) to examine the effect of ethylene on postharvest senescence of  
gladiolus (*Gladiolus gandavensis* cv. Spic and Span). Ethylene production  
and respiration rate of each spike was monitored daily. Ethylene  
production was peaked at 6 days after harvest. Gladiolus spikes were  
placed in ethephon solution, ranging 100, 200 and 400 ppm. Typical  
climacteric pattern of ethylene production, promoted senescence by  
ethephon application, and extended vase life by STS treatment, an  
inhibitor of ethylene action, suggested that ethylene may be involved in  
senescence of cut gladiolus.

IT Major Concepts  
 Bioenergetics (Biochemistry and Molecular Biophysics); Chemical Coordination and Homeostasis; Development; Horticulture (Agriculture)

IT Chemicals & Biochemicals  
 ETHYLENE; SILVER THIOSULFATE

IT Miscellaneous Descriptors  
 CLIMACTERIC; PLANT GROWTH REGULATOR; RESPIRATION; SILVER THIOSULFATE; VASE LIFE

ORGN Super Taxa

*Iridaceae*: Monocotyledones, Angiospermae, Spermatophyta, Plantae

ORGN Organism Name

Gladiolus gandavensis (*Iridaceae*)

ORGN Organism Superterms

angiosperms; monocots; plants; spermatophytes; vascular plants

RN 74-85-1 (ETHYLENE)

23149-52-2 (SILVER THIOSULFATE)

L16 ANSWER 2 OF 5 BIOSIS COPYRIGHT 2001 BIOSIS

AN 1995:377630 BIOSIS

DN PREV199598391930

TI Evaluation of non-climacteric senescence of Gladiolus sp. flowers.

AU Pemberton, G. H.; Nell, Terril A.; Barrett, James E.

CS Dep. Environ. Horticulture, Univ. Fla., Gainesville, FL 32611 USA

SO Hortscience, (1995) Vol. 30, No. 4, pp. 760.

Meeting Info.: 92nd Annual Meeting of the American Society for Horticultural Science and the 40th Annual Congress of the Canadian Society for Horticultural Science Montreal, Quebec, Canada July 30-August 3, 1995

ISSN: 0018-5345.

DT Conference

LA English

IT Major Concepts

Bioenergetics (Biochemistry and Molecular Biophysics); Chemical Coordination and Homeostasis; Development; Horticulture (Agriculture); Metabolism

IT Chemicals & Biochemicals

ETHYLENE

IT Industry

crop industry

IT Miscellaneous Descriptors

ETHYLENE PRODUCTION; HORTICULTURE; MEETING ABSTRACT; POSTHARVEST LIFE; PROTEIN CONTENT; RESPIRATION

ORGN Super Taxa

*Iridaceae*: Monocotyledones, Angiospermae, Spermatophyta, Plantae; Plantae - Unspecified: Plantae

ORGN Organism Name

plant (Plantae - Unspecified); Gladiolus (*Iridaceae*)

ORGN Organism Superterms

angiosperms; monocots; plants; spermatophytes; vascular plants

RN 74-85-1 (ETHYLENE)

L16 ANSWER 3 OF 5 BIOSIS COPYRIGHT 2001 BIOSIS

AN 1994:436271 BIOSIS

DN PREV199497449271

TI Role of ethylene in opening and senescence of Gladiolus sp. flowers.

AU Serek, Margrethe (1); Jones, Rodney B.; Reid, Michael S.

CS (1) Royal Vet. Agric. Univ., Dep. Agric. Sci., Section Horticulture, Rolighedsvej 23, 1958 Frederiksberg C Denmark

SO Journal of the American Society for Horticultural Science, (1994) Vol. 119, No. 5, pp. 1014-1019.

ISSN: 0003-1062.

DT Article

LA English  
 AB The opening and senescence of gladiolus (*Gladiolus* sp.) florets was accompanied by **climacteric** or nonclimacteric patterns of respiration and ethylene production, depending on variety, and whether data were expressed on a fresh-weight or floret basis. A **climacteric** pattern of ethylene production by the youngest buds on the spike (which never opened) was stimulated by cool storage, and was not affected by holding the spikes in a preservative solution containing sucrose. Ethylene treatment had no effect on senescence of the florets of any of the cultivars tested. Pulse treatment of the spikes with silver thiosulfate (STS) improved floret opening but not the life of individual florets. Sucrose and STS had similar but not synergistic effects on floret opening, suggesting that STS improves flower opening in gladiolus by overcoming the effects of carbohydrate depletion.

IT Major Concepts  
     Biochemistry and Molecular Biophysics; Bioenergetics (Biochemistry and Molecular Biophysics); Chemical Coordination and Homeostasis; Horticulture (Agriculture); Metabolism; Reproduction

IT Chemicals & Biochemicals  
     ETHYLENE; SUCROSE; SILVER THIOSULFATE

IT Miscellaneous Descriptors  
     CARBOHYDRATE; HORTICULTURE; RESPIRATION; SILVER THIOSULFATE; SUCROSE

ORGN Super Taxa

*Iridaceae*: Monocotyledones, Angiospermae, Spermatophyta, Plantae; Plantae - Unspecified: Plantae

ORGN Organism Name  
     plant (Plantae - Unspecified); *Gladiolus* sp. (*Iridaceae*)

ORGN Organism Superterms  
     angiosperms; monocots; plants; spermatophytes; vascular plants

RN 74-85-1 (ETHYLENE)  
 57-50-1 (SUCROSE)  
 23149-52-2 (SILVER THIOSULFATE)

L16 ANSWER 4 OF 5 BIOSIS COPYRIGHT 2001 BIOSIS

AN 1981:164819 BIOSIS

DN BA71:34811

TI HISTO PATHOLOGICAL CHANGES AFTER PSEUDOPHAKOS.

AU SUTTON G A; BARRY D R

CS BIRMINGHAM AND MIDLAND EYE HOSPITAL, CHURCH STREET, BIRMINGHAM B3 2NS ENGLAND .

SO OPHTHALMOLOGICA, (1980) 180 (4), 228-233.

CODEN: OPHTAD. ISSN: 0030-3755.

FS BA; OLD

LA English

AB Cataract **extraction** and **iris** clip lens implantation in an 88 yr old woman were followed by hyphema, anterior uveitis and organized exudates around the implant. The globe was enucleated after 15 mo. due to pain and poor visual prognosis. Sections showed an epithelial downgrowth into part of the anterior chamber, associated with a fibrous membrane which had surrounded part of 1 loop of the implant. Atrophy of the iris, adenomatous changes in a ciliary process and an after-cataractous ring were noted. Inflammatory changes were present in the uvea, associated posteriorly with degenerative choroido-retinitis, probably of **arteriosclerotic** origin. The nylon loops of the implant showed areas of biodegradation and were partly fibrosed in. The possible relationship of the various changes is discussed.

IT Miscellaneous Descriptors

    HUMAN HYPHEMA ANTERIOR UVEITIS IRIS ATROPHY DEGENERATIVE CHOROIDO RETINITIS IRIS CLIP LENS IMPLANTATION COMPLICATION INFLAMMATION EPITHELIAL DOWNGROWTH CATARACT EXTRACTION

L16 ANSWER 5 OF 5 BIOSIS COPYRIGHT 2001 BIOSIS

AN 1979:178754 BIOSIS

DN BA67:58754  
TI COMPOUNDS THAT INCREASE OXYGEN DIFFUSION IN PLASMA.  
AU KURYEL R; AKGERMAN A  
CS CHEM. ENG. DEP., EGE UNIV., BORNOVA, IZMIR, TURK.  
SO ATHEROSCLEROSIS, (1978) 29 (2), 131-140.  
CODEN: ATHSBL. ISSN: 0021-9150.  
FS BA; OLD  
LA English  
AB The rate of diffusion of O<sub>2</sub> in [human] blood plasma is increased by adding certain compounds [procaine, clofibrate, vitamin A, crocetin] to plasma at very low concentration levels. Decreased O<sub>2</sub> diffusion rates in plasma causes local hypoxic conditions and this may be important in the pathogenesis of **atherosclerosis**.  
IT Miscellaneous Descriptors  
HUMAN ATHERO SCLEROSIS PROCAINE CLOFIBRATE CROCETIN VITAMIN A HYPOXIA  
RN 59-46-1 (PROCAINE)  
637-07-0 (CLOFIBRATE)  
7782-44-7 (OXYGEN)  
27876-94-4 (CROCETIN)  
68-26-8Q, 11103-57-4Q (VITAMIN A)